BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 19569249)

  • 21. Diagnosis, classification, and cytogenetics of myelodysplastic syndromes.
    Vallespí T; Imbert M; Mecucci C; Preudhomme C; Fenaux P
    Haematologica; 1998 Mar; 83(3):258-75. PubMed ID: 9573680
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Karyotypic identification of abnormal clones preceding morphological changes or occurring with no definite morphological features of myelodysplastic syndrome: a preliminary study.
    Han JY; Theil KS
    Lab Hematol; 2007; 13(1):17-21. PubMed ID: 17353178
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in Western countries.
    Chen B; Zhao WL; Jin J; Xue YQ; Cheng X; Chen XT; Cui J; Chen ZM; Cao Q; Yang G; Yao Y; Xia HL; Tong JH; Li JM; Chen J; Xiong SM; Shen ZX; Waxman S; Chen Z; Chen SJ
    Leukemia; 2005 May; 19(5):767-75. PubMed ID: 15759035
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Classification and clinical findings of myelodysplastic syndromes].
    Tsuruda K; Hasegawa H; Fuchigami M; Uno N; Morinaga Y; Miyazaki Y; Yanagihara K
    Rinsho Byori; 2014 Apr; 62(4):359-68. PubMed ID: 25022065
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Histological and cytogenetic characterization of bone marrow in relation to prognosis and diagnosis of myelodysplastic syndromes.
    Sakuma T; Hayashi Y; Kanomata N; Murayama T; Matsui T; Kajimoto K; Hanioka K; Chihara K; Maeda S
    Pathol Int; 2006 Apr; 56(4):191-9. PubMed ID: 16634964
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Alteration of methylation status of fragile histidine triad gene promoter in patients with myelodysplastic syndrome].
    Yao DM; Qian J; Xu WR; Lin J; Jiang YW; Fei X; Han LX; Wang Y; Cen JN; Chen ZX
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Feb; 25(1):36-9. PubMed ID: 18247301
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Investigation of 305 patients with myelodysplastic syndromes and 20q deletion for associated cytogenetic and molecular genetic lesions and their prognostic impact.
    Bacher U; Haferlach T; Schnittger S; Zenger M; Meggendorfer M; Jeromin S; Roller A; Grossmann V; Krauth MT; Alpermann T; Kern W; Haferlach C
    Br J Haematol; 2014 Mar; 164(6):822-33. PubMed ID: 24372512
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunophenotypic analysis of myelodysplastic syndromes.
    Del Cañizo MC; Fernández ME; López A; Vidriales B; Villarón E; Arroyo JL; Ortuño F; Orfao A; San Miguel JF
    Haematologica; 2003 Apr; 88(4):402-7. PubMed ID: 12681967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of mitochondrial DNA in 104 patients with myelodysplastic syndromes.
    Wulfert M; Küpper AC; Tapprich C; Bottomley SS; Bowen D; Germing U; Haas R; Gattermann N
    Exp Hematol; 2008 May; 36(5):577-86. PubMed ID: 18439489
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-.
    Mallo M; Arenillas L; Espinet B; Salido M; Hernández JM; Lumbreras E; del Rey M; Arranz E; Ramiro S; Font P; González O; Renedo M; Cervera J; Such E; Sanz GF; Luño E; Sanzo C; González M; Calasanz MJ; Mayans J; García-Ballesteros C; Amigo V; Collado R; Oliver I; Carbonell F; Bureo E; Insunza A; Yañez L; Muruzabal MJ; Gómez-Beltrán E; Andreu R; León P; Gómez V; Sanz A; Casasola N; Moreno E; Alegre A; Martín ML; Pedro C; Serrano S; Florensa L; Solé F
    Haematologica; 2008 Jul; 93(7):1001-8. PubMed ID: 18591625
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of myelodysplastic syndrome and aplastic anemia by immunostaining of p53 and hemoglobin F and karyotype analysis: differential diagnosis between refractory anemia and aplastic anemia.
    Iwasaki T; Murakami M; Sugisaki C; Sobue S; Ohashi H; Asano H; Suzuki M; Nakamura S; Ito M; Murate T
    Pathol Int; 2008 Jun; 58(6):353-60. PubMed ID: 18477214
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serial assessment of suspected myelodysplastic syndromes: significance of flow cytometric findings validated by cytomorphology, cytogenetics, and molecular genetics.
    Kern W; Haferlach C; Schnittger S; Alpermann T; Haferlach T
    Haematologica; 2013 Feb; 98(2):201-7. PubMed ID: 22929975
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Unique cytogenetic features of primary myelodysplastic syndromes in Chinese patients.
    Li L; Liu XP; Nie L; Yu MH; Zhang Y; Qin TJ; Xiao ZJ
    Leuk Res; 2009 Sep; 33(9):1194-8. PubMed ID: 19128829
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluating the prognosis of patients with myelodysplastic syndromes.
    Aul C; Giagounidis A; Germing U; Ganser A
    Ann Hematol; 2002 Sep; 81(9):485-97. PubMed ID: 12373348
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Chromosomal structural changes in patients with myelodysplastic syndrome].
    Yu Y; Liu XP; Liu SH; Yu MH; Zhang Y; Xiao ZJ
    Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(38):2693-7. PubMed ID: 18167247
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of flow cytometric immunophenotyping in myelodysplastic syndromes.
    Pagnucco G; Giambanco C; Gervasi F
    Ann N Y Acad Sci; 2006 Nov; 1089():383-94. PubMed ID: 17261782
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunophenotypic features of granulocytes, monocytes, and blasts in myelodysplastic syndromes.
    Moon HW; Huh JW; Lee M; Hong KS; Chung WS
    Korean J Lab Med; 2010 Apr; 30(2):97-104. PubMed ID: 20445324
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunophenotype in chronic myelomonocytic leukemia: is it closer to myelodysplastic syndromes or to myeloproliferative disorders?
    Subirá D; Font P; Villalón L; Serrano C; Askari E; Góngora E; Castañón S; Gonzalo R; Mata R; Román A; Llamas P
    Transl Res; 2008 May; 151(5):240-5. PubMed ID: 18433705
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic application and clinical significance of FCM progress scoring system based on immunophenotyping in CD34+ blasts in myelodysplastic syndromes.
    Xu F; Guo J; Wu LY; He Q; Zhang Z; Chang CK; Li X
    Cytometry B Clin Cytom; 2013; 84(4):267-78. PubMed ID: 23554290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conventional cytogenetics and fluorescence in situ hybridization in persistent cytopenias and myelodysplastic syndromes in childhood.
    Touliatou V; Kolialexi A; Tsangaris GT; Moschovi M; Polychronopoulou S; Mavrou A
    Anticancer Res; 2004; 24(6):3945-9. PubMed ID: 15736436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.